Truist analyst Jailendra Singh upgraded Veeva (VEEV) to Buy from Hold with a $275 price target Market share shifts in the top 20 pharma have largely played out, with migration-related revenue impacts likely deferred beyond FY27, the analyst tells investors in a research note. Combined with strong execution in growth areas like Crossix and early AI traction, Veeva is positioned for durable growth and margin stability, making current valuations attractive from a risk/reward perspective, the firm argues.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV: